RayKnowChina Research Map
Shortlist

Cancer

Hepatocellular carcinoma

肝细胞癌HCC

A primary cancer of the liver's main cells (hepatocytes). Tumours range from well differentiated, with cells that look like normal liver cells, to poorly differentiated.

Definition adapted from MeSH (US National Library of Medicine)

hospitals in mainland China
194

with a paper from 2016–2025 or a registered study

cities
62

where those hospitals are

open trials in China
371

ClinicalTrials.gov, 8 Nov 2026

Mainland China accounts for 53% of the world's English-language research papers on hepatocellular carcinoma, 2021–2025 (41% in 2016–2020), and 36% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

194 hospitals in 62 cities

Order: papers led on hepatocellular carcinoma, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 16 papers or 1 trial on hepatocellular carcinoma, or was a site in 8 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Beijing17
  2. Shanghai16
  3. Guangzhou15
  4. Shenzhen8
  5. Hangzhou7
  6. Nanjing7
  7. Changsha6
  8. Fuzhou6
  9. Jinan6
  10. Wuhan6

Each opens hepatocellular carcinoma in that city. 52 more cities are in the menu below.

  1. Zhongshan Hospital, Fudan University

    复旦大学附属中山医院Shanghai

    408 papers led
  2. 392 papers led
  3. 281 papers led
  4. First Affiliated Hospital, Zhejiang University

    浙江大学医学院附属第一医院Hangzhou

    258 papers led
  5. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    238 papers led
  6. 219 papers led
  7. Eastern Hepatobiliary Surgery Hospital

    海军军医大学第三附属医院(东方肝胆外科医院)Shanghai

    214 papers led
  8. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    184 papers led
  9. 171 papers led
  10. 169 papers led
  11. Guangxi Medical University Cancer Hospital

    广西医科大学附属肿瘤医院Nanning

    149 papers led
  12. 145 papers led
    No open trial led
  13. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    144 papers led
  14. 135 papers led
    No open trial led
  15. Nanfang Hospital

    南方医科大学南方医院Guangzhou

    127 papers led
  16. 122 papers led
  17. Xiangya Hospital

    中南大学湘雅医院Changsha

    119 papers led
  18. 119 papers led
    No open trial led
  19. Jiangsu Province Hospital

    江苏省人民医院(南医大一附院)Nanjing

    117 papers led
  20. 108 papers led
    No open trial led
  21. Renji Hospital

    上海交通大学医学院附属仁济医院Shanghai

    104 papers led
  22. 103 papers led
  23. 101 papers led
    No open trial led
  24. 97 papers led
    No open trial led
  25. 97 papers led
    No open trial led
  26. 96 papers led
  27. 96 papers led
    No open trial led
  28. 95 papers led
  29. First Affiliated Hospital of USTC

    中国科学技术大学附属第一医院(安徽省立医院)Hefei

    91 papers led
  30. 88 papers led
  31. 87 papers led
    No open trial led
  32. 84 papers led
  33. Sir Run Run Shaw Hospital

    浙江大学医学院附属邵逸夫医院Hangzhou

    83 papers led
  34. 80 papers led
  35. 76 papers led
  36. 76 papers led
    No open trial led
  37. 73 papers led
    No open trial led
  38. Beijing Ditan Hospital, Capital Medical University

    首都医科大学附属北京地坛医院Beijing

    72 papers led
    No open trial led
  39. 70 papers led
    No open trial led
  40. 68 papers led
  41. Beijing Youan Hospital, Capital Medical University

    首都医科大学附属北京佑安医院Beijing

    67 papers led
    No open trial led
  42. Hangzhou First People's Hospital

    杭州市第一人民医院Hangzhou

    67 papers led
    No open trial led
  43. 66 papers led
  44. Sun Yat-sen Memorial Hospital

    中山大学孙逸仙纪念医院Guangzhou

    66 papers led
  45. 65 papers led
  46. 64 papers led
  47. 63 papers led
    No open trial led
  48. 62 papers led
  49. First Hospital of China Medical University

    中国医科大学附属第一医院Shenyang

    61 papers led
  50. Shengjing Hospital of China Medical University

    中国医科大学附属盛京医院Shenyang

    60 papers led
  51. 59 papers led
    No open trial led
  52. 59 papers led
  53. Zhongda Hospital, Southeast University

    东南大学附属中大医院Nanjing

    59 papers led
  54. Harbin Medical University Cancer Hospital

    哈尔滨医科大学附属肿瘤医院Harbin

    58 papers led
    No open trial led
  55. Xijing Hospital

    空军军医大学西京医院Xi'an

    58 papers led
    No open trial led
  56. 57 papers led
    No open trial led
  57. Southwest Hospital, Army Medical University

    陆军军医大学第一附属医院(西南医院)Chongqing

    57 papers led
    No open trial led
  58. Second Xiangya Hospital

    中南大学湘雅二医院Changsha

    55 papers led
    No open trial led
  59. 54 papers led
  60. Fujian Cancer Hospital

    福建省肿瘤医院Fuzhou

    54 papers led
    No open trial led
  61. 54 papers led
  62. Zhujiang Hospital

    南方医科大学珠江医院Guangzhou

    54 papers led
  63. 51 papers led
  64. Hainan General Hospital / Hainan Medical University hospitals

    海南医学院附属医院/海南省人民医院Haikou

    51 papers led
    No open trial led
  65. Hunan Provincial People's Hospital

    湖南省人民医院(湖南师范大学附属第一医院)Changsha

    50 papers led
    No open trial led
  66. 49 papers led
    No open trial led
  67. Fujian Medical University Union Hospital

    福建医科大学附属协和医院Fuzhou

    47 papers led
    No open trial led
  68. 46 papers led
    No open trial led
  69. 45 papers led
  70. 45 papers led
    No open trial led
  71. Tianjin First Central Hospital

    天津市第一中心医院Tianjin

    45 papers led
    No open trial led
  72. 43 papers led
  73. 42 papers led
  74. 42 papers led
    No open trial led
  75. 41 papers led
    No open trial led
  76. 41 papers led
    No open trial led
  77. Third Xiangya Hospital

    中南大学湘雅三医院Changsha

    41 papers led
    No open trial led
  78. 40 papers led
    No open trial led
  79. 39 papers led
  80. 38 papers led
    No open trial led
  81. 36 papers led
    No open trial led
  82. Shanghai General Hospital

    上海市第一人民医院Shanghai

    36 papers led
  83. 36 papers led
    No open trial led
  84. 35 papers led
    No open trial led
  85. 35 papers led
    No open trial led
  86. 35 papers led
  87. Ruijin Hospital

    上海交通大学医学院附属瑞金医院Shanghai

    35 papers led
  88. 35 papers led
  89. Henan Cancer Hospital

    河南省肿瘤医院Zhengzhou

    34 papers led
  90. 33 papers led
  91. 32 papers led
    No open trial led
  92. First Affiliated Hospital of Shandong First Medical University

    山东第一医科大学第一附属医院(山东省千佛山医院)Jinan

    32 papers led
    No open trial led
  93. 31 papers led
    No open trial led
  94. 31 papers led
    No open trial led
  95. Ningbo Medical Center Lihuili Hospital

    宁波市医疗中心李惠利医院Ningbo

    31 papers led
  96. 30 papers led
    No open trial led
  97. Beijing Tongren Hospital

    首都医科大学附属北京同仁医院Beijing

    30 papers led
    No open trial led
  98. 30 papers led
    No open trial led
  99. Tianjin Third Central Hospital

    天津市第三中心医院Tianjin

    30 papers led
    No open trial led
  100. 29 papers led
    No open trial led
  101. 29 papers led
    No open trial led
  102. Second Hospital of Dalian Medical University

    大连医科大学附属第二医院Dalian

    29 papers led
    No open trial led
  103. 29 papers led
    No open trial led
  104. 28 papers led
    No open trial led
  105. 27 papers led
    No open trial led
  106. 27 papers led
    No open trial led
  107. Shanghai Sixth People's Hospital

    上海市第六人民医院Shanghai

    27 papers led
    No open trial led
  108. Shanghai Tenth People's Hospital

    上海市第十人民医院Shanghai

    27 papers led
    No open trial led
  109. Taizhou Hospital, Wenzhou Medical University

    温州医科大学附属台州医院Taizhou

    27 papers led
    No open trial led
  110. Zhongshan Hospital, Xiamen University

    厦门大学附属中山医院Xiamen

    27 papers led
    No open trial led
  111. 25 papers led
  112. 25 papers led
    No open trial led
  113. 25 papers led
    No open trial led
  114. 25 papers led
    No open trial led
  115. 24 papers led
    No open trial led
  116. 24 papers led
  117. 24 papers led
  118. Chongqing University Cancer Hospital

    重庆大学附属肿瘤医院Chongqing

    23 papers led
    No open trial led
  119. Jinling Hospital

    东部战区总医院(金陵医院)Nanjing

    23 papers led
  120. 23 papers led
    No open trial led
  121. Xinqiao Hospital, Army Medical University

    陆军军医大学第二附属医院(新桥医院)Chongqing

    23 papers led
    No open trial led
  122. 22 papers led
    No open trial led
  123. 22 papers led
    No open trial led
  124. 22 papers led
    No open trial led
  125. 22 papers led
    No open trial led
  126. 22 papers led
    No open trial led
  127. 22 papers led
    No open trial led
  128. 22 papers led
    No open trial led
  129. 21 papers led
  130. China-Japan Union Hospital, Jilin University

    吉林大学白求恩第三医院(中日联谊医院)Changchun

    21 papers led
    No open trial led
  131. 21 papers led
    No open trial led
  132. 21 papers led
  133. Xinhua Hospital

    上海交通大学医学院附属新华医院Shanghai

    21 papers led
    No open trial led
  134. 20 papers led
  135. 20 papers led
  136. Shuguang Hospital

    上海中医药大学附属曙光医院Shanghai

    20 papers led
    No open trial led
  137. 19 papers led
    No open trial led
  138. Changhai Hospital

    海军军医大学第一附属医院(长海医院)Shanghai

    19 papers led
    No open trial led
  139. 19 papers led
  140. Sichuan Cancer Hospital

    四川省肿瘤医院Chengdu

    19 papers led
  141. 18 papers led
    No open trial led
  142. 18 papers led
    No open trial led
  143. 17 papers led
    No open trial led
  144. 17 papers led
    No open trial led
  145. 17 papers led
    No open trial led
  146. 16 papers led
    No open trial led
  147. 16 papers led
    No open trial led
  148. Hunan Cancer Hospital

    湖南省肿瘤医院Changsha

    16 papers led
  149. Jiangsu Cancer Hospital

    江苏省肿瘤医院Nanjing

    16 papers led
    No open trial led
  150. 16 papers led
    No open trial led
  151. 16 papers led
    No open trial led
  152. Taihe Hospital

    十堰市太和医院Shiyan

    16 papers led
    No open trial led
  153. Tangdu Hospital

    空军军医大学唐都医院Xi'an

    16 papers led
    No open trial led
  154. Yichang Central People's Hospital

    宜昌市中心人民医院Yichang

    16 papers led
    No open trial led
  155. Zhuhai People's Hospital

    珠海市人民医院Zhuhai

    16 papers led
    No open trial led
  156. 15 papers led
    No open trial led
  157. 15 papers led
  158. Changzheng Hospital

    海军军医大学第二附属医院(长征医院)Shanghai

    15 papers led
  159. 15 papers led
    No open trial led
  160. Xuanwu Hospital

    首都医科大学宣武医院Beijing

    15 papers led
    No open trial led
  161. 14 papers led
    No open trial led
  162. 12 papers led
  163. 12 papers led
    No open trial led
  164. 11 papers led
    No open trial led
  165. Longhua Hospital

    上海中医药大学附属龙华医院Shanghai

    11 papers led
    No open trial led
  166. Xuzhou Central Hospital

    徐州市中心医院Xuzhou

    11 papers led
    No open trial led
  167. 10 papers led
    No open trial led
  168. 9 papers led
    No open trial led
  169. 9 papers led
  170. 9 papers led
  171. 8 papers led
    No open trial led
  172. 8 papers led
    No open trial led
  173. Hubei Cancer Hospital

    湖北省肿瘤医院Wuhan

    8 papers led
    No open trial led
  174. Jiangxi Cancer Hospital

    江西省肿瘤医院Nanchang

    8 papers led
    No open trial led
  175. Cancer Hospital CAMS – Shenzhen

    中国医学科学院肿瘤医院深圳医院Shenzhen

    6 papers led
  176. Fourth Affiliated Hospital of Zhejiang University

    浙江大学医学院附属第四医院Hangzhou

    6 papers led
    No open trial led
  177. Huai'an First People's Hospital

    淮安市第一人民医院Huai'an

    6 papers led
    No open trial led
  178. Hubei Provincial Hospital

    湖北省人民医院Wuhan

    6 papers led
    No open trial led
  179. 6 papers led
  180. Jilin Cancer Hospital

    吉林省肿瘤医院Changchun

    4 papers led
    No open trial led
  181. Linyi People's Hospital

    临沂市人民医院Linyi

    2 papers led
    No open trial led
  182. Qingdao Central Hospital

    康复大学青岛中心医院Qingdao

    2 papers led
    No open trial led
  183. Shanghai Proton and Heavy Ion Center

    上海市质子重离子医院Shanghai

    2 papers led
    No open trial led
  184. Shenzhen Third People's Hospital

    深圳市第三人民医院Shenzhen

    2 papers led
  185. 1 paper led
  186. Nantong Tumor Hospital

    南通市肿瘤医院Nantong

    1 paper led
    No open trial led
  187. 0 papers led
  188. 0 papers led
    No open trial led
  189. Fuda Cancer Hospital

    广州复大肿瘤医院Guangzhou

    0 papers led
    No open trial led
  190. Guiping People's Hospital

    桂平市人民医院

    0 papers led
  191. Harbin Medical University Hospital

    哈尔滨医科大学附属医院(试验登记未写明哪一家)Harbin

    0 papers led
  192. Jinan Military General Hospital

    中国人民解放军济南军区总医院Jinan

    0 papers led
    No open trial led
  193. 0 papers led
    No open trial led
  194. 0 papers led
    No open trial led

By university or health system 59

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Sun Yat-sen University

    中山大学Guangzhou

    820 papers led
    6 hospitals
  2. Fudan University

    复旦大学Shanghai

    603 papers led
    6 hospitals
  3. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    520 papers led
    6 hospitals
  4. Sichuan University (West China)

    四川大学华西Chengdu

    414 papers led
    5 hospitals
  5. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    413 papers led
    6 hospitals
  6. Guangxi Medical University

    广西医科大学Nanning

    378 papers led
    6 hospitals
  7. Naval Medical University

    海军军医大学Shanghai

    301 papers led
    6 hospitals
  8. Capital Medical University

    首都医科大学Beijing

    290 papers led
    6 hospitals
  9. Fujian Medical University

    福建医科大学Fuzhou

    288 papers led
    6 hospitals
  10. Zhengzhou University

    郑州大学Zhengzhou

    284 papers led
    6 hospitals
  11. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    260 papers led
    6 hospitals
  12. Nanjing Medical University

    南京医科大学Nanjing

    250 papers led
    6 hospitals
  13. Central South University (Xiangya)

    中南大学湘雅Changsha

    246 papers led
    6 hospitals
  14. Southern Medical University

    南方医科大学Guangzhou

    239 papers led
    6 hospitals
  15. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    233 papers led
    5 hospitals
  16. Chongqing Medical University

    重庆医科大学Chongqing

    224 papers led
    6 hospitals
  17. Wenzhou Medical University

    温州医科大学Wenzhou

    219 papers led
    6 hospitals
  18. Wuhan University

    武汉大学Wuhan

    194 papers led
    4 hospitals
  19. Xi'an Jiaotong University

    西安交通大学Xi'an

    193 papers led
    6 hospitals
  20. Shandong First Medical University

    山东第一医科大学Jinan

    191 papers led
    6 hospitals
  21. Anhui Medical University

    安徽医科大学Hefei

    184 papers led
    6 hospitals
  22. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    184 papers led
    1 hospital
  23. Nanchang University

    南昌大学Nanchang

    181 papers led
    6 hospitals
  24. Harbin Medical University

    哈尔滨医科大学Harbin

    165 papers led
    6 hospitals
  25. Shandong University

    山东大学Jinan

    157 papers led
    6 hospitals
  26. Tianjin Medical University

    天津医科大学Tianjin

    153 papers led
    6 hospitals
  27. China Medical University (Shenyang)

    中国医科大学Shenyang

    151 papers led
    6 hospitals
  28. Peking University Health Science Center

    北京大学医学部Beijing

    148 papers led
    6 hospitals
  29. Nantong University

    南通大学Nantong

    145 papers led
    1 hospital
  30. Nanjing University

    南京大学Nanjing

    137 papers led
    5 hospitals
  31. Jilin University

    吉林大学Changchun

    135 papers led
    5 hospitals
  32. Soochow University

    苏州大学Suzhou

    135 papers led
    6 hospitals
  33. Guangzhou Medical University

    广州医科大学Guangzhou

    125 papers led
    6 hospitals
  34. 108 papers led
    1 hospital
  35. Jinan University

    暨南大学Guangzhou

    107 papers led
    6 hospitals
  36. Qingdao University

    青岛大学Qingdao

    107 papers led
    5 hospitals
  37. Army Medical University

    陆军军医大学Chongqing

    105 papers led
    4 hospitals
  38. Tongji University

    同济大学Shanghai

    102 papers led
    6 hospitals
  39. Air Force Medical University

    空军军医大学Xi'an

    99 papers led
    6 hospitals
  40. Southwest Medical University

    西南医科大学Luzhou

    97 papers led
    1 hospital
  41. Chongqing University

    重庆大学Chongqing

    84 papers led
    6 hospitals
  42. 82 papers led
    6 hospitals
  43. Xuzhou Medical University

    徐州医科大学Xuzhou

    76 papers led
    6 hospitals
  44. Hebei Medical University

    河北医科大学Shijiazhuang

    74 papers led
    6 hospitals
  45. Xiamen University

    厦门大学Xiamen

    73 papers led
    6 hospitals
  46. Kunming Medical University

    昆明医科大学Kunming

    71 papers led
    6 hospitals
  47. 67 papers led
    3 hospitals
  48. Guilin Medical University

    桂林医学院Guilin

    66 papers led
    1 hospital
  49. Guizhou Medical University

    贵州医科大学Guiyang

    60 papers led
    5 hospitals
  50. Xinjiang Medical University

    新疆医科大学Urumqi

    42 papers led
    5 hospitals
  51. Bengbu Medical University

    蚌埠医科大学Bengbu

    41 papers led
    1 hospital
  52. Guangdong Medical University

    广东医科大学Zhanjiang

    40 papers led
    6 hospitals
  53. Shenzhen University

    深圳大学Shenzhen

    37 papers led
    6 hospitals
  54. Jiangnan University

    江南大学Wuxi

    36 papers led
    2 hospitals
  55. University of Chinese Academy of Sciences

    中国科学院大学Beijing

    35 papers led
    1 hospital
  56. Chengdu University

    成都大学Chengdu

    31 papers led
    1 hospital
  57. Ningxia Medical University

    宁夏医科大学Yinchuan

    31 papers led
    4 hospitals
  58. Shantou University Medical College

    汕头大学医学院Shantou

    25 papers led
    1 hospital
  59. Guangdong Pharmaceutical University

    广东药科大学Guangzhou

    16 papers led
    1 hospital

371

open trials on hepatocellular carcinoma in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 286 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT06794073

    Age 18 years to 80 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  2. Recruiting
    A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07070076

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Jinan UniversityGuangzhou

  3. Recruiting
    NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
    Phase
    Early phase 1
    Started
    2026-01
    Registry
    NCT07295262

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  4. Recruiting
    Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07295275

    Age 18 years to 80 years (registered criteria)

    Led by West China Hospital; 2 listed hospitals as study sitesBeijing, Chengdu, Xuzhou

  5. Recruiting
    Diagnostic Accuracy of Folate-Targeted NIR-II Carbon Dots for Ex Vivo HCC Detection
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07295340

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  6. Recruiting
    Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07310173

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  7. Recruiting
    Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07324824

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  8. Recruiting
    A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07328009

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  9. Recruiting
    First in Human Study of SIM0610 in Solid Tumors
    Phase
    Phase 1
    Started
    2026-01
    Registry
    NCT07348211

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChongqing, Harbin, Shanghai, Shenyang

  10. Recruiting
    A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07351669

    Age 18 years to 75 years (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  11. Recruiting
    The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07381634

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  12. Recruiting
    SBRT Versus Surgical Resection for Small HCC
    Phase
    Phase 3
    Started
    2026-03
    Registry
    NCT07381660

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  13. Recruiting
    Surgery vs. Watch-and-Wait Strategy in Partial & Complete Responders for Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07410715

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  14. Recruiting
    Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07413354

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  15. Recruiting
    Adjuvant TACE in HCC With High-risk Recurrence Factors
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT07417397

    Age 18 years to 70 years (registered criteria)

    Led by Guangxi Medical University Cancer HospitalNanning

  16. Recruiting
    A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07422753

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  17. Recruiting
    PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07463248

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  18. Recruiting
    A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07475026

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  19. Recruiting
    A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2026-04
    Registry
    NCT07478302

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesFuzhou, Nanning

  20. Recruiting
    MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Registry
    NCT07479485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Tianjin, Zhengzhou

  21. Recruiting
    A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Registry
    NCT07482059

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  22. Recruiting
    Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07483359

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of China Medical UniversityShenyang

  23. Recruiting
    TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07487662

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  24. Recruiting
    A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
    Phase
    Phase 2/Phase 3
    Started
    2026-03
    Registry
    NCT07490262

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  25. Recruiting
    An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07493044

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  26. Recruiting
    Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-03
    Registry
    NCT07495735

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Wenzhou Medical UniversityWenzhou

  27. Recruiting
    Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07500220

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  28. Recruiting
    Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07501351

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  29. Recruiting
    A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07521852

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesFuzhou, Shanghai

  30. Recruiting
    Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07523529

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenzhen

  31. Recruiting
    Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07536789

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  32. Recruiting
    AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-04
    Registry
    NCT07538882

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  33. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Zhengzhou

  34. Recruiting
    18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
    Phase
    N/A
    Started
    2026-04
    Registry
    NCT07557225

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  35. Recruiting
    Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07560488

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  36. Recruiting
    A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07589244

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  37. Recruiting
    68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2026-06
    Registry
    NCT07590336

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  38. Recruiting
    HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07594340

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  39. Recruiting
    Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07639138

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  40. Recruiting
    TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07658833

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  41. Recruiting
    GPC3-Targeted PET/CT in Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07677774

    Age 18 years to 90 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  42. Recruiting
    68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07760012

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Third HospitalBeijing

  43. Recruiting
    Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07776080

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  44. Recruiting
    Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07793695

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  45. Recruiting
    GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07795437

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  46. Recruiting
    IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07799922

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  47. Recruiting
    Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07801287

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  48. Recruiting
    Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07811687

    Age 18 years to 80 years (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

  49. Recruiting
    Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07840092

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  50. Recruiting
    InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07848750

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  51. Recruiting
    Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-01
    Registry
    NCT06676982

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  52. Recruiting
    HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06737913

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Zhengzhou

  53. Recruiting
    Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-03
    Registry
    NCT06741020

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  54. Recruiting
    A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06742892

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha

  55. Recruiting
    Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06762782

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  56. Recruiting
    Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06766643

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  57. Recruiting
    Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
    Phase
    Phase 2/Phase 3
    Started
    2025-02
    Registry
    NCT06796803

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 1 listed hospital as study siteHarbin, Shanghai

  58. Recruiting
    HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
    Phase
    Phase 2
    Started
    2025-01
    Registry
    NCT06812039

    Age 18 years to 75 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 2 listed hospitals as study sitesFuzhou, Shanghai, Tianjin

  59. Recruiting
    Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06841172

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  60. Recruiting
    A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06844357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  61. Recruiting
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
    Phase
    Phase 1
    Started
    2025-04
    Registry
    NCT06858813

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  62. Recruiting
    HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06860490

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  63. Recruiting
    Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06861114

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  64. Recruiting
    Phase I Study of OriC902 in Treatment of Advanced HCC
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06891742

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing

  65. Recruiting
    Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2025-05
    Registry
    NCT06893887

    Age 18 years to Not stated (registered criteria)

    Led by Nanjing Tianyinshan HospitalNanjing

  66. Recruiting
    TACE Combined Surgery for the Resectable Huge HCC
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT06898398

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  67. Recruiting
    A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT06902389

    Age 18 years to 75 years (registered criteria)

    Led by Eastern Hepatobiliary Surgery HospitalShanghai

  68. Recruiting
    Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06904183

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  69. Recruiting
    Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06904196

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  70. Recruiting
    SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
    Phase
    N/A
    Started
    2025-04
    Registry
    NCT06909708

    Age 18 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  71. Recruiting
    Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-05
    Registry
    NCT06938880

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  72. Recruiting
    Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06940102

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShenyang

  73. Recruiting
    Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06950827

    Age 18 years to Not stated (registered criteria)

    Led by West China HospitalChengdu

  74. Recruiting
    Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT06954116

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  75. Recruiting
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06954467

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changsha, Harbin, Hefei, Nanchang, Shanghai, Shenyang, Zhengzhou

  76. Recruiting
    FGF19 Overexpression Combination Unified Study in HCC-19
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06978933

    Age 18 years to Not stated (registered criteria)

    Led by Renji HospitalShanghai

  77. Recruiting
    A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT06986785

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  78. Recruiting
    Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Registry
    NCT06995105

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  79. Recruiting
    Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT07010198

    Age 35 years to Not stated (registered criteria)

    Led by Zhongshan City People's HospitalZhongshan

  80. Recruiting
    FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07012798

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  81. Recruiting
    Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07014150

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  82. Recruiting
    PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07018518

    Age 18 years to 75 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  83. Recruiting
    A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07039201

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  84. Recruiting
    Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07047586

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  85. Recruiting
    A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07052253

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  86. Recruiting
    PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
    Phase
    Phase 1
    Started
    2025-10
    Registry
    NCT07053072

    Age 18 years to 70 years (registered criteria)

    Led by West China HospitalChengdu

  87. Recruiting
    Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07059936

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  88. Recruiting
    BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07062055

    Age 18 years to 70 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  89. Recruiting
    AI-Based Prediction of HCC Recurrence Patterns After Resection (APAR)
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07062380

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  90. Recruiting
    Study of GV20-0251 in Participants With Solid Tumor Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT07070518

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  91. Recruiting
    Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07077356

    Age 18 years to Not stated (registered criteria)

    Led by West China HospitalChengdu

  92. Recruiting
    Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT07079150

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of Xi'an Jiaotong UniversityXi'an

  93. Recruiting
    Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07099274

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  94. Recruiting
    Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07100392

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  95. Recruiting
    TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100405

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  96. Recruiting
    A Study of GV20-0251 in Advanced or Refractory Solid Tumors
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07106827

    Age 18 years to Not stated (registered criteria)

    Led by West China HospitalChengdu

  97. Recruiting
    Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-08
    Registry
    NCT07123545

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  98. Recruiting
    The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT07141056

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Guilin Medical University; 1 listed hospital as study siteGuilin, Zhanjiang

  99. Recruiting
    Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07147101

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  100. Recruiting
    The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT07147335

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, University of South ChinaHengyang

  101. Recruiting
    The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
    Phase
    Phase 4
    Started
    2025-11
    Registry
    NCT07150624

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  102. Recruiting
    Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07154082

    Age 18 years to 70 years (registered criteria)

    Led by Tongji HospitalWuhan

  103. Recruiting
    ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT07157969

    Age 18 years to Not stated (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  104. Recruiting
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07170345

    Age 18 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai

  105. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  106. Recruiting
    Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT07179900

    Age 18 years to Not stated (registered criteria)

    Led by Fourth Hospital of Hebei Medical UniversityShijiazhuang

  107. Recruiting
    Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07192185

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  108. Recruiting
    GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07209813

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Nanchang, Nanjing, Zhengzhou

  109. Recruiting
    Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
    Phase
    Phase 1/Phase 2
    Started
    2025-12
    Registry
    NCT07227012

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  110. Recruiting
    Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07235410

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  111. Recruiting
    Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07238881

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  112. Recruiting
    Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07239245

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 2 listed hospitals as study sitesBeijing, Shenyang, Zhengzhou

  113. Recruiting
    TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07242417

    Age 18 years to 75 years (registered criteria)

    Led by Beijing GoBroad HospitalBeijing

  114. Recruiting
    Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07243691

    Age 18 years to Not stated (registered criteria)

    Led by Sir Run Run Shaw HospitalHangzhou

  115. Recruiting
    A Study of DEG6498 in Participants With Solid Tumors
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07244835

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou

  116. Recruiting
    Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
    Phase
    Phase 3
    Started
    2025-10
    Registry
    NCT07267806

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  117. Recruiting
    TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07268131

    Age 18 years to 75 years (registered criteria)

    Led by Huashan HospitalShanghai

  118. Recruiting
    JMT106 Injection in the Treatment of Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07275073

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

  119. Recruiting
    Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
    Phase
    Phase 1/Phase 2
    Started
    2025-10
    Registry
    NCT07282184

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  120. Recruiting
    The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
    Phase
    Phase 2/Phase 3
    Started
    2025-10
    Registry
    NCT07285850

    Age 18 years to Not stated (registered criteria)

    Led by Eastern Hepatobiliary Surgery HospitalShanghai

  121. Recruiting
    β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07317414

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College Hospital; 2 listed hospitals as study sitesBeijing, Nanjing, Xuzhou

  122. Recruiting
    DEB-TACE vs cTACE in HCC After TIPS
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07322848

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  123. Recruiting
    NWRD06 DNA Plasmid for HCC After Curative Resection.
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07324304

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Harbin

  124. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  125. Recruiting
    QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07327788

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  126. Recruiting
    Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07331883

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin Hospital; 2 listed hospitals as study sitesChangchun, Shanghai

  127. Recruiting
    Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07337421

    Age 18 years to 75 years (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

  128. Recruiting
    Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07337460

    Age 18 years to 75 years (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

  129. Recruiting
    Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07359586

    Age not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  130. Recruiting
    A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-06
    Registry
    NCT07376707

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  131. Recruiting
    MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07391839

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shanghai, Zhengzhou

  132. Recruiting
    Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07417800

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  133. Recruiting
    Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07436845

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  134. Recruiting
    cfDNA Methylation for Liver Cancer Recurrence Detection
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07466602

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  135. Recruiting
    A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Registry
    NCT07495215

    Age 18 years to 75 years (registered criteria)

    Led by Sir Run Run Shaw HospitalHangzhou

  136. Recruiting
    To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07594964

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  137. Recruiting
    Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07769827

    Age 18 years to Not stated (registered criteria)

    Led by Jinling HospitalNanjing

  138. Recruiting
    Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT07806292

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  139. Recruiting
    Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT07832006

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  140. Recruiting
    Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06215651

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  141. Recruiting
    Immunotherapy for Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT06241326

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  142. Recruiting
    HAIC (Hepatic Artery Infusion Chemotherapy,HAIC)Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT06244225

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  143. Recruiting
    Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
    Phase
    N/A
    Started
    2024-02
    Registry
    NCT06265350

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  144. Recruiting
    A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06280105

    Age 18 years to 75 years (registered criteria)

    Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou

  145. Recruiting
    Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT06280313

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  146. Recruiting
    Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06301399

    Age 17 years to 79 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  147. Recruiting
    A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06307925

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou

  148. Recruiting
    Phase 2 Study of WGI-0301 for Advanced HCC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06309485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Chengdu, Hangzhou, Harbin, Nanchang, Wuhan

  149. Recruiting
    Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
    Phase
    Phase 4
    Started
    2024-04
    Registry
    NCT06311929

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  150. Recruiting
    Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06313190

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  151. Recruiting
    Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06349317

    Age 18 years to 75 years (registered criteria)

    Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou

  152. Recruiting
    A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06349980

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  153. Recruiting
    DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
    Phase
    Phase 4
    Started
    2024-10
    Registry
    NCT06353126

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  154. Recruiting
    Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT06360042

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  155. Recruiting
    Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
    Phase
    Phase 1
    Started
    2024-03
    Registry
    NCT06363006

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  156. Recruiting
    A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06371157

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Hangzhou, Nanjing, Zhengzhou

  157. Recruiting
    Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06382103

    Age not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  158. Recruiting
    Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06389422

    Age 18 years to 90 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  159. Recruiting
    Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06397222

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  160. Recruiting
    DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06397235

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  161. Recruiting
    Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06406634

    Age 18 years to 75 years (registered criteria)

    Led by Hunan Cancer HospitalChangsha

  162. Recruiting
    A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
    Phase
    Early phase 1
    Started
    2024-10
    Registry
    NCT06418659

    Age 18 years to Not stated (registered criteria)

    Led by Changzheng HospitalShanghai

  163. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  164. Recruiting
    Recurrent Liver Cancer: Reconceptualization and Reevaluation
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06430983

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Nanjing Medical UniversityNanjing

  165. Recruiting
    Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06446154

    Age 18 years to Not stated (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  166. Recruiting
    Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06454578

    Age 18 years to Not stated (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  167. Recruiting
    Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06461624

    Age 18 years to 70 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  168. Recruiting
    Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06467799

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  169. Recruiting
    Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2024-06
    Registry
    NCT06470256

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  170. Recruiting
    Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib
    Phase
    N/A
    Started
    2024-01
    Registry
    NCT06478927

    Age 18 years to 75 years (registered criteria)

    Led by Henan Cancer HospitalZhengzhou

  171. Recruiting
    Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06482801

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  172. Recruiting
    TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06485466

    Age 18 years to 80 years (registered criteria)

    Led by Sichuan Cancer HospitalChengdu

  173. Recruiting
    Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06492395

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  174. Recruiting
    Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06492408

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  175. Recruiting
    Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06498622

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  176. Recruiting
    HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-10
    Registry
    NCT06515314

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  177. Recruiting
    Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06519578

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  178. Recruiting
    A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06530251

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Jinan

  179. Recruiting
    Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06537908

    Age 18 years to 90 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  180. Recruiting
    Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-09
    Registry
    NCT06542796

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  181. Recruiting
    Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06544083

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  182. Recruiting
    Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06550921

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  183. Recruiting
    Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06561399

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 2 listed hospitals as study sitesFuzhou

  184. Recruiting
    Oral Fecal Microbiota Transplantation in Advanced Hepatocellular Carcinoma After Progression on ICI-TKI Therapy
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06563947

    Age 18 years to 75 years (registered criteria)

    Led by Shenzhen Third People's HospitalShenzhen

  185. Recruiting
    Neoadjuvant Triple Therapy for Resectable HCC
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06569498

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen

  186. Recruiting
    Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06581315

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  187. Recruiting
    Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06602011

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen

  188. Recruiting
    mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
    Phase
    Phase 2
    Started
    2024-02
    Registry
    NCT06607107

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  189. Recruiting
    The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06609850

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  190. Recruiting
    dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06609863

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  191. Recruiting
    Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06609876

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  192. Recruiting
    A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)
    Phase
    Phase 3
    Started
    2024-10
    Registry
    NCT06618664

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei

  193. Recruiting
    TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
    Phase
    N/A
    Started
    2024-10
    Registry
    NCT06622031

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  194. Recruiting
    Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06623474

    Age 18 years to 80 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  195. Recruiting
    HAIC Compared With TACE in Huge Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-10
    Registry
    NCT06641713

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  196. Recruiting
    Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-10
    Registry
    NCT06644430

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  197. Recruiting
    Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
    Phase
    Phase 2/Phase 3
    Started
    2024-11
    Registry
    NCT06644937

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  198. Recruiting
    Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
    Phase
    Early phase 1
    Started
    2024-11
    Registry
    NCT06652243

    Age 18 years to 70 years (registered criteria)

    Led by Shanghai General HospitalShanghai

  199. Recruiting
    Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06653062

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  200. Recruiting
    Mts105 for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06689540

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  201. Recruiting
    Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2024-02
    Registry
    NCT06694636

    Age 25 years to 75 years (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  202. Recruiting
    Y-90 SIRT for Unresectable HCC Larger Than 7cm
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06707233

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  203. Recruiting
    PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06742424

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  204. Recruiting
    The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06746194

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  205. Recruiting
    Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06849180

    Age 18 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  206. Recruiting
    Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06864221

    Age 18 years to 80 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  207. Recruiting
    A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
    Phase
    Phase 4
    Started
    2024-12
    Registry
    NCT06930573

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  208. Recruiting
    Digital Early Warning System for Acute Lung Injury in Liver Surgery
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT07070362

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Chongqing

  209. Recruiting
    An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT07101237

    Age 18 years to 70 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  210. Recruiting
    Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical Application of Immune Mechanisms in Liver Cancer
    Phase
    Not given
    Started
    2024-10
    Registry
    NCT07838415

    Age 18 years to 80 years (registered criteria)

    Led by Tongji HospitalWuhan

  211. Recruiting
    Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05475613

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  212. Recruiting
    A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
    Phase
    Phase 3
    Started
    2023-01
    Registry
    NCT05489289

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  213. Recruiting
    Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC
    Phase
    N/A
    Started
    2023-05
    Registry
    NCT05596630

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  214. Recruiting
    Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2023-01
    Registry
    NCT05613478

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  215. Recruiting
    Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
    Phase
    N/A
    Started
    2023-02
    Registry
    NCT05738980

    Age 18 years to 75 years (registered criteria)

    Led by Beijing HospitalBeijing

  216. Recruiting
    Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
    Phase
    Phase 2
    Started
    2023-03
    Registry
    NCT05751343

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  217. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  218. Recruiting
    Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
    Phase
    Not given
    Started
    2023-03
    Registry
    NCT05870969

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin HospitalShanghai

  219. Recruiting
    Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05917431

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  220. Recruiting
    Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
    Phase
    Phase 2
    Started
    2023-07
    Registry
    NCT05920863

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  221. Recruiting
    GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2023-01
    Registry
    NCT05926726

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  222. Recruiting
    Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT05954897

    Age 18 years to Not stated (registered criteria)

    Led by Guangdong Provincial People's HospitalGuangzhou

  223. Recruiting
    Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT05970666

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Xiamen UniversityXiamen

  224. Recruiting
    TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
    Phase
    N/A
    Started
    2023-08
    Registry
    NCT05984511

    Age 18 years to 75 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  225. Recruiting
    Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
    Phase
    Phase 3
    Started
    2023-08
    Registry
    NCT05985798

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  226. Recruiting
    SIRT for Potentially Resectable HCC
    Phase
    N/A
    Started
    2023-08
    Registry
    NCT05994859

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  227. Recruiting
    Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06031285

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  228. Recruiting
    Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
    Phase
    Phase 3
    Started
    2023-10
    Registry
    NCT06041477

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  229. Recruiting
    Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06060769

    Age 18 years to Not stated (registered criteria)

    Led by Fifth Affiliated Hospital of Sun Yat-sen UniversityZhuhai

  230. Recruiting
    Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
    Phase
    Not given
    Started
    2023-11
    Registry
    NCT06157060

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 3 listed hospitals as study sitesGuangzhou

  231. Recruiting
    Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
    Phase
    Phase 3
    Started
    2023-07
    Registry
    NCT06172205

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  232. Recruiting
    HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT06187961

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  233. Recruiting
    DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06190665

    Age 18 years to 80 years (registered criteria)

    Led by Zhongda Hospital, Southeast University; 1 listed hospital as study siteBeijing, Nanjing

  234. Recruiting
    FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
    Phase
    Phase 3
    Started
    2023-12
    Registry
    NCT06201065

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  235. Recruiting
    Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06219096

    Age 18 years to 75 years (registered criteria)

    Led by West China HospitalChengdu

  236. Recruiting
    Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma
    Phase
    Early phase 1
    Started
    2023-09
    Registry
    NCT06383520

    Age 18 years to 65 years (registered criteria)

    Led by Union HospitalWuhan

  237. Recruiting
    A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2023-04
    Registry
    NCT06508307

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  238. Recruiting
    Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT06559761

    Age 18 years to 80 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  239. Recruiting
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    Phase
    Phase 1
    Started
    2023-10
    Registry
    NCT06560827

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  240. Recruiting
    Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA.
    Phase
    Not given
    Started
    2023-05
    Registry
    NCT06746701

    Age 18 years to 65 years (registered criteria)

    Led by Xiangya Hospital; 2 listed hospitals as study sitesChangsha, Guangzhou, Hengyang

  241. Recruiting
    Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2023-03
    Registry
    NCT06788353

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  242. Recruiting
    Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
    Phase
    Phase 2
    Started
    2023-10
    Registry
    NCT06904014

    Age 18 years to 70 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  243. Recruiting
    A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2022-02
    Registry
    NCT05155189

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou, Zhengzhou

  244. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  245. Recruiting
    Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
    Phase
    Phase 1/Phase 2
    Started
    2022-02
    Registry
    NCT05323201

    Age 18 years to 70 years (registered criteria)

    Led by Affiliated Hospital of Xuzhou Medical UniversityXuzhou

  246. Recruiting
    A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2022-08
    Registry
    NCT05409482

    Age 18 years to 75 years (registered criteria)

    Led by Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhou

  247. Recruiting
    CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection
    Phase
    N/A
    Started
    2022-05
    Registry
    NCT05433467

    Age 18 years to Not stated (registered criteria)

    Led by Northern Jiangsu People's HospitalYangzhou

  248. Recruiting
    Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2022-07
    Registry
    NCT05444478

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChangsha

  249. Recruiting
    Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
    Phase
    N/A
    Started
    2022-08
    Registry
    NCT05484908

    Age 18 years to 65 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  250. Recruiting
    Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05608213

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  251. Recruiting
    Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2022-11
    Registry
    NCT05620706

    Age 40 years to 70 years (registered criteria)

    Led by Shenzhen University General HospitalShenzhen

  252. Recruiting
    Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Registry
    NCT05652920

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Hangzhou, Shanghai

  253. Recruiting
    Clinical Outcomes of HBeAg-negative CHB Patients With Indeterminate Phase
    Phase
    Not given
    Started
    2022-12
    Registry
    NCT05661786

    Age 18 years to Not stated (registered criteria)

    Led by Nanjing Drum Tower HospitalNanjing

  254. Recruiting
    Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy
    Phase
    N/A
    Started
    2022-05
    Registry
    NCT05887661

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  255. Recruiting
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    Phase
    Not given
    Started
    2022-09
    Registry
    NCT06822413

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

  256. Recruiting
    Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
    Phase
    Phase 2
    Started
    2022-07
    Registry
    NCT06870942

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  257. Recruiting
    Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
    Phase
    N/A
    Started
    2021-02
    Registry
    NCT04777942

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  258. Recruiting
    Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2021-01
    Registry
    NCT04803318

    Age 18 years to 85 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  259. Recruiting
    Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2021-03
    Registry
    NCT04952272

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  260. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

  261. Recruiting
    The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy
    Phase
    Early phase 1
    Started
    2021-09
    Registry
    NCT05035108

    Age 30 years to 80 years (registered criteria)

    Led by Sir Run Run Shaw HospitalHangzhou

  262. Recruiting
    GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2021-09
    Registry
    NCT05047510

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesLuzhou, Zhuhai

  263. Recruiting
    Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2021-09
    Registry
    NCT05057845

    Age 18 years to Not stated (registered criteria)

    Led by Fudan University Shanghai Cancer CenterShanghai

  264. Recruiting
    Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
    Phase
    Phase 2/Phase 3
    Started
    2021-06
    Registry
    NCT05062837

    Age 18 years to 75 years (registered criteria)

    Led by Guangxi Medical University Cancer HospitalNanning

  265. Recruiting
    Antiviral Therapy for Patients With Liver Cancer After Surgery
    Phase
    Not given
    Started
    2021-12
    Registry
    NCT05466565

    Age 18 years to 65 years (registered criteria)

    Led by Xiangya HospitalChangsha

  266. Recruiting
    HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2021-01
    Registry
    NCT06333561

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  267. Recruiting
    RFA Plus Carrizumab vs Carrizumab Alone for HCC
    Phase
    Phase 2
    Started
    2020-08
    Registry
    NCT04150744

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  268. Recruiting
    Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
    Phase
    Phase 2
    Started
    2020-12
    Registry
    NCT04615143

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  269. Recruiting
    Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
    Phase
    Phase 2
    Started
    2020-11
    Registry
    NCT04770207

    Age 18 years to 99 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  270. Recruiting
    Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
    Phase
    Not given
    Started
    2020-05
    Registry
    NCT05520788

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  271. Recruiting
    Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2020-05
    Registry
    NCT05713994

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Fujian Medical UniversityQuanzhou

  272. Recruiting
    Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2019-01
    Registry
    NCT03949231

    Age 18 years to 80 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  273. Recruiting
    To Compare the Efficacy of Microwave Ablation and Laparoscopic Hepatectomy for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2019-12
    Registry
    NCT04365751

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  274. Recruiting
    Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2019-01
    Registry
    NCT07782632

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of USTCHefei

  275. Recruiting
    The Overall Survival of Patients With Unresectable HCC in Real-life
    Phase
    Not given
    Started
    2018-07
    Registry
    NCT03612726

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  276. Recruiting
    Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
    Phase
    Phase 2/Phase 3
    Started
    2018-11
    Registry
    NCT03755739

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  277. Recruiting
    Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC
    Phase
    Not given
    Started
    2018-06
    Registry
    NCT06876753

    Age 18 years to 80 years (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  278. Recruiting
    GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
    Phase
    Phase 1
    Started
    2017-07
    Registry
    NCT03198546

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical University; 1 listed hospital as study siteGuangzhou

  279. Recruiting
    Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
    Phase
    Phase 2/Phase 3
    Started
    2009-12
    Registry
    NCT02851784

    Age not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  280. Not yet recruiting
    NK521 in the Treatment of Advanced Solid Tumors
    Phase
    Early phase 1
    Started
    2027-01
    Registry
    NCT07657416

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHefei

  281. Not yet recruiting
    Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
    Phase
    Phase 2
    Started
    2027-09
    Registry
    NCT07691645

    Age 18 years to 75 years (registered criteria)

    Led by Zhejiang Cancer HospitalHangzhou

  282. Not yet recruiting
    Integration of Imaging, Molecular, Pathological, and Clinical Outcome Data in Hepatocellular Carcinoma.
    Phase
    Not given
    Started
    2027-01
    Registry
    NCT07912853

    Age 18 years to Not stated (registered criteria)

    Led by West China HospitalChengdu

  283. Not yet recruiting
    FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07314372

    Age 18 years to Not stated (registered criteria)

    Led by Nanjing Drum Tower HospitalNanjing

  284. Not yet recruiting
    Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07324473

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Chongqing Medical UniversityChongqing

  285. Not yet recruiting
    Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07328802

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  286. Not yet recruiting
    A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT07337031

    Age 18 years to 75 years (registered criteria)

    Led by Eastern Hepatobiliary Surgery HospitalShanghai

  287. Not yet recruiting
    Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma
    Phase
    Early phase 1
    Started
    2026-01
    Registry
    NCT07352345

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  288. Not yet recruiting
    Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07356037

    Age 18 years to 85 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteChengdu

  289. Not yet recruiting
    Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07363356

    Age 18 years to 70 years (registered criteria)

    Led by Eastern Hepatobiliary Surgery HospitalShanghai

  290. Not yet recruiting
    A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2026-01
    Registry
    NCT07368023

    Age 16 years to Not stated (registered criteria)

    Led by Ningbo Medical Center Lihuili HospitalNingbo

  291. Not yet recruiting
    A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
    Phase
    Phase 2/Phase 3
    Started
    2026-03
    Registry
    NCT07392866

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  292. Not yet recruiting
    Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
    Phase
    N/A
    Started
    2026-04
    Registry
    NCT07480382

    Age 18 years to 80 years (registered criteria)

    Led by West China HospitalChengdu

  293. Not yet recruiting
    Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
    Phase
    Early phase 1
    Started
    2026-03
    Registry
    NCT07487402

    Age 19 years to 75 years (registered criteria)

    Led by First Affiliated Hospital, Zhejiang UniversityHangzhou

  294. Not yet recruiting
    Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07537777

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  295. Not yet recruiting
    Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07537946

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  296. Not yet recruiting
    Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
    Phase
    N/A
    Started
    2026-04
    Registry
    NCT07537959

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  297. Not yet recruiting
    Denosumab Strategy for Liver Cancer With Bone Metastases
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07537972

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  298. Not yet recruiting
    Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection
    Phase
    Early phase 1
    Started
    2026-03
    Registry
    NCT07553767

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNingbo

  299. Not yet recruiting
    Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07557914

    Age 18 years to 80 years (registered criteria)

    Led by First Hospital of China Medical UniversityShenyang

  300. Not yet recruiting
    Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07558200

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  301. Not yet recruiting
    Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07565415

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  302. Not yet recruiting
    YMN-A02 for Advanced Primary Hepatocellular Carcinoma.
    Phase
    Phase 1
    Started
    2026-07
    Registry
    NCT07580261

    Age 18 years to 70 years (registered criteria)

    Led by West China HospitalChengdu

  303. Not yet recruiting
    Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions
    Phase
    Not given
    Started
    2026-04
    Registry
    NCT07582419

    Age 18 years to 85 years (registered criteria)

    Led by First Hospital of Jilin UniversityChangchun

  304. Not yet recruiting
    A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07583316

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  305. Not yet recruiting
    Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07596134

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Nanchang, Taizhou

  306. Not yet recruiting
    Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07657273

    Age 18 years to Not stated (registered criteria)

    Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou

  307. Not yet recruiting
    A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07682272

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  308. Not yet recruiting
    A Study of Combination Therapy in Patients With Resectable Liver Cancer
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07684040

    Age 18 years to Not stated (registered criteria)

    Led by Affiliated Hospital of Guangdong Medical UniversityZhanjiang

  309. Not yet recruiting
    A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2026-11
    Registry
    NCT07691762

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  310. Not yet recruiting
    The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07724951

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai

  311. Not yet recruiting
    AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07729618

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  312. Not yet recruiting
    AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07732504

    Age 18 years to Not stated (registered criteria)

    Led by Tongji HospitalWuhan

  313. Not yet recruiting
    SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07749859

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMSBeijing

  314. Not yet recruiting
    Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Registry
    NCT07761286

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHarbin

  315. Not yet recruiting
    Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07768085

    Age 18 years to Not stated (registered criteria)

    Led by Shengjing Hospital of China Medical UniversityShenyang

  316. Not yet recruiting
    HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07780357

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Friendship HospitalBeijing

  317. Not yet recruiting
    A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion
    Phase
    Phase 4
    Started
    2026-08
    Registry
    NCT07790419

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhengzhou UniversityZhengzhou

  318. Not yet recruiting
    ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07813572

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteNanjing

  319. Not yet recruiting
    JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
    Phase
    Phase 3
    Started
    2026-10
    Registry
    NCT07823348

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shanghai

  320. Not yet recruiting
    Heterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07824765

    Age 18 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  321. Not yet recruiting
    TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07836309

    Age 16 years to Not stated (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  322. Not yet recruiting
    Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07847671

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  323. Not yet recruiting
    Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
    Phase
    Phase 1
    Started
    2026-11
    Registry
    NCT07861425

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  324. Not yet recruiting
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-12
    Registry
    NCT07866612

    Age 18 years to 80 years (registered criteria)

    Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai

  325. Not yet recruiting
    Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II Study
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07870772

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  326. Not yet recruiting
    Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07880106

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  327. Not yet recruiting
    SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07882056

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  328. Not yet recruiting
    NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
    Phase
    Phase 2
    Started
    2026-11
    Registry
    NCT07919717

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  329. Not yet recruiting
    FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
    Phase
    Phase 1/Phase 2
    Started
    2025-01
    Registry
    NCT06409637

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  330. Not yet recruiting
    Liver Cancer Prognosis Investigation Study
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06623734

    Age 18 years to 80 years (registered criteria)

    Led by Sun Yat-sen University Cancer CenterGuangzhou

  331. Not yet recruiting
    Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06708650

    Age 18 years to 75 years (registered criteria)

    Led by Guiping People's Hospital

  332. Not yet recruiting
    SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06739317

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  333. Not yet recruiting
    Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2025-01
    Registry
    NCT06749678

    Age 18 years to 75 years (registered criteria)

    Led by Sun Yat-sen Memorial HospitalGuangzhou

  334. Not yet recruiting
    A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2025-01
    Registry
    NCT06779461

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBengbu, Guangzhou, Lanzhou, Nanjing, Shanghai, Tianjin, Zhengzhou

  335. Not yet recruiting
    Fusing Ultrasound and Magnetic Resonance Imaging to Intelligently Plan Highly Conformal Ablation Thermal Field for Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT06798194

    Age 18 years to Not stated (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  336. Not yet recruiting
    QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06822985

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  337. Not yet recruiting
    A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06823050

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteZhengzhou

  338. Not yet recruiting
    Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Registry
    NCT06896396

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  339. Not yet recruiting
    Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06900478

    Age 18 years to 80 years (registered criteria)

    Led by Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  340. Not yet recruiting
    A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06935175

    Age 18 years to 75 years (registered criteria)

    Led by Zhongshan Hospital, Fudan UniversityShanghai

  341. Not yet recruiting
    Relationship Between FGF19 Overexpression and Disease Prognosis
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT06938451

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  342. Not yet recruiting
    Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07010588

    Age 18 years to 75 years (registered criteria)

    Led by Peking University People's Hospital; 8 listed hospitals as study sitesBeijing, Changchun, Chongqing, Harbin, Jinan, Qingdao, Wuhan, Xi'an

  343. Not yet recruiting
    HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07045558

    Age 18 years to 75 years (registered criteria)

    Led by Renji HospitalShanghai

  344. Not yet recruiting
    Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07064668

    Age 18 years to 80 years (registered criteria)

    Led by Tongji HospitalWuhan

  345. Not yet recruiting
    29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07100236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wenzhou, Zhengzhou

  346. Not yet recruiting
    A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07131501

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  347. Not yet recruiting
    A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07156617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHaikou, Nanchang, Zhengzhou

  348. Not yet recruiting
    Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07157306

    Age 18 years to 80 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  349. Not yet recruiting
    The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib:A Prospective, Single-arm, Multicenter, Observational Study
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07180459

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHaikou

  350. Not yet recruiting
    EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
    Phase
    Phase 1/Phase 2
    Started
    2025-09
    Registry
    NCT07187284

    Age 18 years to 75 years (registered criteria)

    Led by Zhongda Hospital, Southeast UniversityNanjing

  351. Not yet recruiting
    Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07192848

    Age 18 years to Not stated (registered criteria)

    Led by Cancer Hospital CAMS – ShenzhenShenzhen

  352. Not yet recruiting
    A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07239986

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei, Shanghai

  353. Not yet recruiting
    TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07350070

    Age 18 years to 75 years (registered criteria)

    Led by Tongji Hospital; 4 listed hospitals as study sitesFuzhou, Jinan, Nanning, Qingdao, Wuhan

  354. Not yet recruiting
    Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07350824

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  355. Not yet recruiting
    Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07352007

    Age 18 years to 75 years (registered criteria)

    Led by Shandong Cancer Hospital and InstituteJinan

  356. Not yet recruiting
    Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06089369

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  357. Not yet recruiting
    A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT06196775

    Age 18 years to 75 years (registered criteria)

    Led by Harbin Medical University HospitalHarbin

  358. Not yet recruiting
    Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06317896

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou

  359. Not yet recruiting
    Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06449846

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou

  360. Not yet recruiting
    CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Registry
    NCT06641453

    Age 18 years to 70 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  361. Not yet recruiting
    A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
    Phase
    Phase 2
    Started
    2024-12
    Registry
    NCT06724263

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

  362. Not yet recruiting
    Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study
    Phase
    N/A
    Started
    2023-03
    Registry
    NCT05602974

    Age 18 years to 75 years (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou

  363. Not yet recruiting
    SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
    Phase
    Phase 3
    Started
    2023-03
    Registry
    NCT05718232

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou

  364. Not yet recruiting
    A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
    Phase
    Phase 2/Phase 3
    Started
    2023-09
    Registry
    NCT05976568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai

  365. Not yet recruiting
    Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06041490

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College HospitalBeijing

  366. Enrolling by invitation
    JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT06882876

    Age 18 years to 75 years (registered criteria)

    Led by Xiangya HospitalChangsha

  367. Enrolling by invitation
    Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07290764

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial HospitalFuzhou

  368. Enrolling by invitation
    A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06647264

    Age 18 years to 80 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  369. Enrolling by invitation
    Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06712017

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  370. Enrolling by invitation
    A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
    Phase
    Phase 2
    Started
    2021-12
    Registry
    NCT05441475

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  371. Enrolling by invitation
    The Efficacy of Sequential RT After Triple Therapy for uHCC
    Phase
    Not given
    Started
    2020-11
    Registry
    NCT07052448

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial HospitalFuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Before contacting a hospital

The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.

Where these numbers come from

Papers

14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions